We are live on ! Find out more
XTLB

XTL Biopharmaceuticals
XTLB

3 hedge funds and large institutions have $20.7K invested in XTL Biopharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

2.75% less ownership

Funds ownership: 3.07% → 0.32% (-2.8%)

50% less funds holding

Funds holding: 6 → 3 (-3)

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

88% less capital invested

Capital invested by funds: $175K → $20.7K (-$155K)

Holders
3
Holders Change
-3
Holders Change %
-50%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
+$621
2
UBS Group
UBS Group
Switzerland
+$322

Top Sellers

Rank Fund Capital Flow
1
NI
Noked Israel
Israel
-$120K
2
SP
SmartHarvest Portfolios
Washington
-$32.2K
3
GI
GAMMA Investing
California
-$5.6K
4
TRCT
Tower Research Capital (TRC)
New York
-$588
5
Morgan Stanley
Morgan Stanley
New York
-$24

XTLB Hedge Fund Activity: Q2 2026 in Review

3 of the 8,344 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q2 2026, worth a combined $20.7K — down 88% from $175K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of XTLB and 1 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 1 added.

The largest buyer was RhumbLine Advisers, adding an estimated $621. The largest seller was Noked Israel, exiting entirely with an estimated $120K sold.

  • 3 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q2 2026, down from 6 in Q1 2026.
  • Funds reported $20.7K of XTL Biopharmaceuticals stock for Q2 2026, down 88% quarter-over-quarter.
  • 1 fund opened new XTL Biopharmaceuticals positions in Q2 2026 and 4 closed out, a net change of -3 holders.
  • The largest XTL Biopharmaceuticals buyer in Q2 2026 was RhumbLine Advisers, an estimated $621 added.
  • The largest XTL Biopharmaceuticals seller in Q2 2026 was Noked Israel, an estimated $120K sold.

Based on aggregated 13F filings for Q2 2026.